Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tao, Lichan ^a   Shen, Sutong ^a   Fu, Siyi ^b   Fang, Hongyi ^a   Wang, Xiuzhi ^a   Das, Saumya ^c   Sluijter, Joost P G ^d   Rosenzweig, Anthony ^c   Zhou, Yonglan ^a   Kong, Xiangqing ^a   Xiao, Junjie ^a,b   Li, Xinli ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; MUSCLE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QILIQIANGXIN;

ANIMAL; DRUG EFFECTS; HEART VENTRICLE REMODELING; MALE; METABOLISM; MOUSE; MYOCARDIAL INFARCTION; PATHOLOGY;

ANIMALS; DRUGS, CHINESE HERBAL; MALE; MICE; MUSCLE PROTEINS; MYOCARDIAL INFARCTION; PPAR GAMMA; VENTRICULAR REMODELING;

EID: 84939634287     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08374     Document Type: Article

References (39)

1. Heusch, G. et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 383, 1933-1943 (2014).
2. Mezzaroma, E. et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in themouse. Proc Natl Acad Sci US A. 108, 19725-19730 (2011).
3. Seropian, I. M., Toldo, S., Van Tassell, B. W. & Abbate, A. Anti-inflammatory strategies for ventricular remodeling following st-segment elevation acute myocardial infarction. J Am Coll Cardiol. 63, 1593-1603 (2014).
4. Vilahur, G. et al. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 50, 522-533 (2011).
5. Devaux, Y. et al. Microrna-150: Anovel marker of left ventricular remodeling after acute myocardial infarction. Cir Cardiovasc Genet. 6, 290-298 (2013).
6. Oba, T. et al. Cardiac-specific deletion of socs-3 prevents development of left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 59, 838-852 (2012).
7. Tang, T. T. et al. Regulatory t cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol. 107, 232 (2012).
8. Muhlestein, J. B. Adverse left ventricular remodelling after acute myocardial infarction: Is there a simple treatment that really works? Eur Heart J. 35, 144-146 (2014).
9. Fraccarollo, D., Galuppo, P. & Bauersachs, J. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc Res. 94, 293-303 (2012).
10. Li, X. et al. A multicenter, randomized, double-blind, parallel-group, placebocontrolled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 62, 1065-1072 (2013).
11. Chen, F., Wu, J. L., Fu, G. S., Mou, Y. & Hu, S. J. Chronic treatment with qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats. J Cardiovasc Pharmacol Ther. Doi:10.1177/1074248414537 705 (2014).
12. Tao, L., Shen, S. & Li, X. Future prospects of qiliqiangxin on heart failure: Epigenetic regulation of regeneration. Front Genet. 4, 221 (2013).
13. Chinese Society of Cardiology of Chinese Medical Association & Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2014. Zhonghua Xin Xue Guan Bing Za Zhi. 42, 98-122 (2014).
14. Zhang, J. et al. Protective effect of qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats. Evid Based Complement Alternat Med. 2013, 378298 (2013).
15. Zou, Y. et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. J Cardiovasc Pharmacol. 59, 268-280 (2012).
16. Xiao, H., Song, Y., Li, Y., Liao, Y. H. & Chen, J. Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction. Cell Immunol. 260, 51-55 (2009).
17. Liu, W. et al. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am J Hypertens. 25, 250-260 (2012).
18. Janicki, J. S. & Levick, S. P. The convergence of ancient chinese medicine with modern therapeutics to prevent cardiac fibrosis. Am J Hypertens. 25, 139 (2012).
19. Tang, W. H. & Huang, Y. Cardiotonic modulation in heart failure: Insights from traditional chinese medicine. J Am Coll Cardiol. 62, 1073-1074 (2013).
20. Dixon, J. A. & Spinale, F. G. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 73, 47-68 (2011).
21. Konstam,M.A. et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 4, 98-108 (2011).
22. Higgins, L. S. & Depaoli, A. M. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr. 91, 267S-272S (2010).
23. Morrison, A. & Li, J. PPAR-r and AMPK - advantageous targets for myocardial ischemia/reperfusion therapy. Biochem Pharmacol. 82, 195-200 (2011).
24. Abdelrahman, M., Sivarajah, A. & Thiemermann, C. Beneficial effects of ppargamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res. 65, 772-781 (2005).
25. Huss, J. M. & Kelly, D. P. Nuclear receptor signaling and cardiac energetics. Cir Res. 95, 568-578 (2004).
26. Madrazo, J. A. & Kelly, D. P. The ppar trio: Regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardio. 44, 968-975 (2008).
27. Wu, X. et al. Genetic and pharmacological inhibition of rheb1-mtorc1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol. 182, 2005-2014 (2013).
28. Das, S. et al. Pathological role of serum-and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation. 126, 2208-2219 (2012).
29. Melman, Y. F., Shah, R. & Das, S. Micrornas in heart failure: Is the picture becoming less mirky? Cir Heart Fail. 7, 203-214 (2014).
30. Houtgraaf, J. H. et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res. 113, 153-166 (2013).
31. Duan, S. Z., Ivashchenko, C. Y., Usher, M. G. &Mortensen, R.M. Ppar-gamma in the cardiovascular system. PPAR Res. 2008, 745804 (2008).
32. Huang, J. V., Greyson, C. R. & Schwartz, G. G. Ppar-gamma as a therapeutic target in cardiovascular disease: Evidence and uncertainty. J Lipid Res. 53, 1738-1754 (2012).
33. Pfeffer, M. A. & Braunwald, E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81, 1161-1172 (1990).
34. Surder, D. et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function. Circulation. 127, 1968-1979 (2013).
35. Wayman, N. S. et al. Ligands of the peroxisome proliferator-activated receptors (ppar-gamma and ppar-alpha) reduce myocardial infarct size. FASEB J. 16, 1027-1040 (2002).
36. Drosatos, K. et al. Peroxisome proliferator-activated receptor-gamma activation prevents sepsis-related cardiac dysfunction and mortality in mice. Cir Heart Fail. 6, 550-562 (2013).
37. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 356, 2457-2471 (2007).
38. Hiatt, W. R., Kaul, S. & Smith, R. J. The cardiovascular safety of diabetes drugs - insights from the rosiglitazone experience. N Engl J Med. 369, 1285-1287 (2013).
39. Duan, S. Z., Ivashchenko, C. Y., Russell, M. W.,Milstone, D. S.&Mortensen, R. M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferatoractivated receptor-gamma both induce cardiac hypertrophy in mice. Cir Res. 97, 372-379 (2005).